SCGB1A1 and asthma: Intriguing preclinical and clinical results in COPD, asthma, and CLAD suggest that reduced CCSP is a biomarker of disease or disease progression, and mechanistic studies have demonstrated the direct or indirect anti-inflammatory effects of CCSP on immune and epithelial cells in the lung.